Table 1 Summary of the included studies (RCT randomized controlled trial, SSI surgical site infection, iNPWT negative pressure wound therapy, SD standard dressing, Cht chemotherapy, BMI body mass index, IFX infliximab)
Topic | Author | Year | Study type | Intervention | Setting | Number of patients | N. of IP | Results |
|---|---|---|---|---|---|---|---|---|
Transplanted patients | Dean P.G. | 2004 | RCT | Sirolimus vs tacrolimus | Kidney transplant | 123 | All | Higher rate of SSI in sirolimus |
Siskind E. | 2012 | Prospective | Partial incision closure | Kidney transplant | 104 | All | No SSI | |
Shahrestani S. | 2018 | Meta-analysis | Sirolimus, BMI, different surgical incisions | Kidney and pancreas transplant | 17821 | All | Higher rate of hernia in sirolimus | |
Gurusamy | 2014 | Review of RCTs | Bowel decontamination, Pre- and probiotics, G-CSF | Liver transplant | 614 | All | No difference in SSI or complication rate | |
Shrestha M.S. | 2016 | Systematic review | NPWT for complication | Kidney transplant | 22 | All | Heterogeneous | |
D’Souza K. | 2019 | Syst rev. of retrospective | Drain vs. no drain | Kidney transplant | 1640 | All | No difference in SSI or complication rate | |
Berry | 2019 | RCT | 72 h-long antibiotic prophylaxis vs intraoperatory antibiotic alone | Liver transplant | 97 | All | ||
Colorectal cancer | Kabbinavar F. | 2005 | RCT | CHT +/− bevacizumab | Metastatic colorectal cancer | 209 | All | / |
Hurvitz H. | 2004 | RCT | CHT +/− bevacizumab | Metastatic colorectal cancer | 813 | All | / | |
Scappaticci F.A. | 2005 | Pooled data from RCT | CHT +/− bevacizumab | Metastatic colorectal cancer | 1132 | All | SSI: 13% BZ+CH vs 3.4% CH alone | |
Curran T. | 2018 | Retrospective | iNPWT vs SD | High-risk open colorectal surgery | 315 | 61 (chronic steroid/metastatic cancer) | SSI: 7% iNPWT vs 15% SD | |
Crohn disease | Bafford A.C. | 2013 | Retrospective | Patients on immunomodulatory therapy | Crohn disease | 196 | 127 (on drugs) | Same rate of SSI |
Canedo J. | 2010 | Retrospective | Patients on IFX, other drugs or assuming no drugs | Crohn disease | 225 | 150 (IFX or other drugs) | No difference in SSI | |
Trauma | Costa M.L. | 2020 | RCT | iNPWT vs SD | High-risk patients | 1629 | Not specified | No difference in SSI rate |
Masden D. | 2012 | RCT | iNPWT vs SD | High-risk patients | 81 | 7 | No difference in SSI rate | |
Mixed High-risk population | BlackHam A.U. | 2013 | Retrospective | iNPWT vs SD | Abdominal oncological surgery | 191 | 76 (neoadjuvant cht) | SSI: 6.7% iNPWT vs 19.5% SD |
Javed A.A. | 2019 | RCT | iNPWT vs SD | High-risk pancreatico-duodenectomy | 123 | 77 (neoadjuvant cht) | SSI: iNPWT 9% vs 31.1% SD | |
Murphy P.B. | 2019 | RCT | iNPWT vs SD | Open colorectal | 288 | 9 | No difference in SSI rate | |
O’Leary D.P. | 2017 | RCT | iNPWT vs SD | Abdominal surgery | 49 | Not specified | SSI: iNPWT 8.3% vs 32% SD | |
Li P.-Y. | 2017 | RCT | iNPWT vs SD | Abdominal, colorectal surgery | 71 | Not specified | SSI: iNPWT 3% vs 23.7% SD | |
Shen P. | 2017 | RCT | iNPWT vs SD | Abdominal, oncological surgery | 265 | Excluded | No difference in SSI rate | |
Mixed High-risk population | Strugala and Martin | 2017 | Meta-analysis (RCT + observational) | iNPWT vs SD | All specialities | 1863 | Not specified | SSI: iNPWT 4.8% vs 9.7% SD |
Zwanenburg P.R. | 2019 | Meta-analysis (RCT + observational but only RCT reported) | iNPWT vs SD | All specialities + subgroup analysis | 4398 | Not specified | No advantage in NPWT if stratified for surgical specialties | |
Kuper T.M. | 2020 | Meta-analysis of RCTs | iNPWT vs SD | Open abdominal | 792 | Not specified | No difference in SSI rate | |
Sahebally S. | 2018 | Meta-analysis (RCT + observational) | iNPWT vs SD | Open abdominal | 1187 | Not specified | NPWT > SD pooled OR 0.25 |